Introduction: The effectiveness of video-observed therapy (VOT) for treating tuberculosis (TB) has not been measured in low- and middle-income countries (LMICs), where >95% of TB cases and deaths occur. In this study, we analyse the effectiveness and patient cost-difference of VOT compared to clinic-based directly observed therapy (DOT) in improving medication adherence in Moldova, a LMIC in Eastern Europe.
Methods: The study was a two-arm individually randomised trial with 197 TB patients (n=99 DOT control group; n=98 VOT treatment group; multidrug-resistant TB cases were excluded). The primary outcome was observed medication adherence, measured by the number of days that a patient failed to be observed adhering to medication for every 2-week period during the course of their treatment.
Results: VOT significantly decreased nonadherence by 4 days (95% CI 3.35-4.67 days, p<0.01) per 2-week period: 5.24 days missed per 2-week period for DOT and 1.29 days for VOT. VOT patients spent MDL 504 (∼EUR 25) (95% CI MDL 277-730, p<0.01) and 58 h (95% CI 48-68 h, p<0.01) less on their treatment. In addition, VOT increased self-reported satisfaction with treatment. We found no significant results pertaining to treatment success, patient wellbeing or patient employment status and some evidence of an increase in side-effects.
Discussion: In this trial, VOT increased observed medication adherence for TB patients in Moldova, a LMIC, when compared to clinic-based DOT. Additionally, VOT significantly reduced the time and money patients spent on their treatment.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1183/13993003.00493-2020 | DOI Listing |
Alzheimers Dement
December 2024
Senior Doc, Orange, CA, USA.
Background: Measuring the effectiveness of dementia care programs is essential for ensuring quality care and aligning with value-based care principles, especially in practical, real-world clinical settings. A Delphi method, a consensus-building approach among experts, was used to identify practical metrics for evaluating dementia programs. The expert panel comprised a clinical psychologist, two healthcare executives, and a physician experienced in person-centered care for older adults in residential and facility settings.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Michigan State University, East Lansing, MI, USA.
Background: Confabulation, the fabrication of details with short lucid intervals, hinders the diagnosis of Alzheimer's and other dementias. This case report explores the complexities of diagnosing and managing Alzheimer's dementia in a culturally diverse patient exhibiting fluctuating memory and confabulation, emphasizing challenges heightened by cultural and linguistic factors.
Case: An 84-year-old African descent man resided with his family in the United States, independent in his basic daily activities but struggling with instrumental tasks due to memory impairment.
Alzheimers Dement
December 2024
University of Waterloo, Waterloo, ON, Canada.
Background: The Medication Review in Cognitive Impairment and Dementia (MedRevCiD) checklist is a new tool designed to assist health care professionals in optimizing medication use in individuals with Mild Cognitive Impairment (MCI) or dementia. It consists of 6 domains, each of which addresses a specific medication use issue such as medication management and adherence. The primary objective of this study was to compare the mean number of drug-related problems (DRPs) identified with MedRevCiD Checklist to the Medication Appropriateness Index (MAI) in older adults attending a primary care-based memory clinic.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of Waterloo, Waterloo, ON, Canada.
Background: Up to 30% of hospitalizations in older adults living with Mild Cognitive Impairment (MCI) and dementia are attributed to drug-related problems (DRPs), including adverse drug reactions, drug interactions, potentially inappropriate medication (PIM) use, and medication non-adherence. This study categorizes the identified DRPs according to the Pharmaceutical Care Network Europe (PCNE) Classification for DRPs version 9.1.
View Article and Find Full Text PDFClin Kidney J
January 2025
Pharmacoepidemiology Unit, Department of Clinical Pharmacology, Amiens-Picardie University Medical Center, Amiens, France.
Background: We sought to comprehensively describe drug-related components associated with acute kidney injury (AKI) in patients with chronic kidney disease (CKD), describing the incidence of drug-related AKI, the proportion of preventable AKI, identified the various drugs potentially associated with it, explored the risk factors, and assessed the 1-year incidences of the recurrence of drug-related AKI, kidney failure, and death.
Methods: CKD-REIN is a French national prospective cohort of 3033 nephrology outpatients with a confirmed diagnosis of CKD (eGFR <60 ml/min/1.73 m²).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!